According to the latest financial results, Zenotech Laboratories reported a standalone net loss of ₹0.46 crore in the quarter ended June 2026, marking a significant improvement from the net loss of ₹0.99 crore recorded in the corresponding quarter of the previous financial year. The company's Board of Directors approved these unaudited standalone financial results on July 28, 2026, with the results reviewed by the Audit Committee and subjected to a limited review by statutory auditors G S K A & Co. who issued an unmodified review conclusion under Standard on Review Engagements (SRE) 2410.
The company's revenue from operations increased by 11.11% to ₹9.60 crore in the quarter ended June 2026, compared to ₹8.64 crore in the same period of the previous financial year. This growth was primarily driven by steady rental income from Sun Pharmaceutical Industries Limited and consistent other operating income. The company's total income stood at ₹1,104.79 lakh, up from ₹1,023.16 lakh in Q1FY25, with other operating income remaining stable at ₹101.58 lakh against ₹100.41 lakh previously. The stability in other operating income, which constitutes roughly 10% of total income, underscores the importance of the company's asset-leasing strategy.
Despite revenue growth, the company faced significant expense pressures with total expenses surging 30% to ₹1,164.86 lakh from ₹895.48 lakh in the same period last year. Employee benefit expenses increased substantially to ₹491.63 lakh compared to ₹353.56 lakh in Q1FY25, while other expenses rose to ₹483.00 lakh from ₹364.55 lakh. Additionally, depreciation and amortization increased to ₹190.23 lakh from ₹177.37 lakh in the previous year. The widening gap between total income growth of 8% and expense growth of 30% indicates pressure on operational margins, with employee costs being the primary driver of this divergence.
According to latest market data, Zenotech Laboratories has a market capitalization of ₹281 crore and is currently trading at ₹2.94 times its book value. The company maintains a low return on equity of 4.25% over the last 3 years, with promoter holding at 68.8%. The company's debtor days have increased from 55.2 to 73.5 days, indicating some working capital challenges. As per the company's financial statements, it operates as a biotechnology products manufacturer and is part of Sun Pharmaceuticals Industries Ltd, focusing on manufacturing and marketing of pharmaceuticals and bio-pharmaceutical products, particularly specializing in oncology, bio-technology and general injectables.
